Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Glatiramer acetate during early pregnancy: A prospective cohort study.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Selective inhibition of CCR7- TEM cells activation by a novel peptide targeting Kv1.3 in a rat EAE model.
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
ALSUntangled No. 8: Low dose naltrexone for ALS.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Pathological mechanisms in progressive multiple sclerosis.
Biogen Reports Another Tecfidera PML Case
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Pages